Article
Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Therapeutic drug monitoring - 1 Dec 2012
Fangbin Zhang, Xiang Gao, Minhu Chen, Liang Ding, Feng Xu, Min Huang, Pinjin Hu
Abstract excerpt
BACKGROUND AND AIMS: Not all of the adverse effects to thiopurine therapy can be explained by thiopurine methyltransferase (TPMT) polymorphisms. This study was intended to evaluate the value of TPMT genotype and phenotype measurement during the first year of thiopurine therapy. METHODS: Consecutive patients with inflammatory bowel disease (IBD) who were receiving azathioprine or 6-mercaptopurine were followed up...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
